GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vigil Neuroscience Inc (NAS:VIGL) » Definitions » Cash From Discontinued Investing Activities

Vigil Neuroscience (Vigil Neuroscience) Cash From Discontinued Investing Activities : $0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Vigil Neuroscience Cash From Discontinued Investing Activities?

Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Vigil Neuroscience's cash from discontinued investing activities for the three months ended in Mar. 2024 was $0.00 Mil. It means Vigil Neuroscience received $0.00 Mil from discontinued investing activities. Vigil Neuroscience's cash from discontinued investing activities for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.

Vigil Neuroscience Cash From Discontinued Investing Activities Historical Data

The historical data trend for Vigil Neuroscience's Cash From Discontinued Investing Activities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vigil Neuroscience Cash From Discontinued Investing Activities Chart

Vigil Neuroscience Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Cash From Discontinued Investing Activities
- - - -

Vigil Neuroscience Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash From Discontinued Investing Activities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Vigil Neuroscience Cash From Discontinued Investing Activities Calculation

Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Cash From Discontinued Investing Activities for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vigil Neuroscience Cash From Discontinued Investing Activities Related Terms

Thank you for viewing the detailed overview of Vigil Neuroscience's Cash From Discontinued Investing Activities provided by GuruFocus.com. Please click on the following links to see related term pages.

Vigil Neuroscience (Vigil Neuroscience) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vigil Neuroscience Inc (NAS:VIGL) » Definitions » Cash From Discontinued Investing Activities
Comparable Companies
VNDA ACIU OCUL OVID NUVB IGMS YMAB EYPT AVIR XERS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
100 Forge Road, Suite 700, Watertown, MA, USA, 02472
Website
https://www.vigilneuro.com
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families.
Executives
Ivana Magovcevic-liebisch director, officer: President and CEO 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Christopher Silber officer: Chief Medical Officer C/O VIGIL NEUROSCIENCE, INC., 100 FORGE ROAD, SUITE 700, WATERTOWN MA 02472
Budd Haeberlein Samantha L. director VIGIL NEUROSCIENCE, INC., 100 FORGE ROAD, SUITE 700, WATERTOWN MA 02472
Gray David L. F. officer: Chief Science Officer VIGIL NEUROSCIENCE, INC., 100 FORGE ROAD, SUITE 700, WATERTOWN MA 02472
Spyridon Papapetropoulos officer: Chief Medical Officer C/O ADAMAS PHARMACEUTICALS, INC., 1900 POWELL ST., SUITE 1000, EMERYVILLE CA 94608
Suzanne Louise Bruhn director C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746
Clay Thorp director C/O HATTERAS VENTURE PARTNERS III, LP, 280 S. MANGUM ST., SUITE 350, DURHAM NC 27701
Evan Thackaberry officer: SVP, Head of Early Development VIGIL NEUROSCIENCE, INC., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Jennifer Lynn Ziolkowski officer: Chief Financial Officer C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Christopher Verni officer: General Counsel VIGIL NEUROSCIENCE, INC., 1 BROADWAY, 7TH FLOOR, SUITE 07-300, CAMBRIDGE MA 02142
Mary Thistle director C/O VIACELL, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
Vida Ventures Gp Iii, L.l.c. 10 percent owner 455 MARKET STREET, SUITE 1420, SAN FRANCISCO CA 94105
Northpond Ventures Gp, Llc 10 percent owner 7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814
Stefan Vitorovic director C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Bruce Booth director 890 WINTER STREET, SUITE 320, WALTHAM MA 02451